The short answer is this: retatrutide looks promising for body composition, but current research does not prove that it directly builds muscle or fully prevents muscle loss
Esser N, Paquot N, Scheen AL, Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease
However, recent research has raised questions about whether some GLP-1 medications, especially semaglutide, may be associated with a higher risk of a rare but serious eye condition called NAION
The global peptide therapeutics market was valued at nearly $50 billion in 2024, and its projected to reach up to around $84 billion by 2034.1 One of the most well-known peptides in recent years is semaglutide (Ozempic), a glucagon-like peptide-1 receptor agonist (GLP-1) used for the treatment of type 2 diabetes.2 However, semaglutide is just one of many different peptides that could potentially lead to health benefits